Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.40 |
| ▸ | NPY4R | P50391 | 6/20 | 0.40 |
| ▸ | NPY1R | P25929 | 5/20 | 0.40 |
| ▸ | NPY2R | P49146 | 3/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20015437 | 0.92 | NPY5R (0.40) | NPY5RNPY4RNPY1RNPY2RSIRT2 | |
| SCHEMBL16646739 | 0.88 | NPY5R (0.39) | NPY5RNPY4RNPY1RNPY2RSIRT2 | |
| SCHEMBL16646743 | 0.88 | SIRT2 (0.43) | NPY5RNPY4RNPY1RNPY2RSIRT2 | |
| SCHEMBL25064729 | 0.88 | NPY5R (0.44) | NPY5RNPY4RNPY1RNPY2RSIRT2 | |
| SCHEMBL25064681 | 0.87 | NPY5R (0.43) | NPY5RNPY4RNPY1RNPY2RSIRT2 | |
| SCHEMBL21152621 | 0.86 | SIRT2 (0.43) | NPY5RNPY4RNPY1RNPY2RSIRT2 | |
| SCHEMBL19841675 | 0.86 | NPY5R (0.39) | NPY5RNPY4RNPY1RNPY2RSIRT2 | |
| SCHEMBL21152794 | 0.85 | NPY4R (0.42) | NPY5RNPY4RNPY1RNPY2RSIRT2 | |
| SCHEMBL21754508 | 0.85 | NPY4R (0.47) | NPY5RNPY4RNPY1RNPY2RFURIN | |
| SCHEMBL25826708 | 0.85 | NPY4R (0.47) | NPY5RNPY4RNPY1RNPY2RFURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187119-A1 | Drug-Conjugates, Conjugation Methods, And Uses Thereof | VIVASOR, INC. | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187119-A1 | Drug-Conjugates, Conjugation Methods, And Uses Thereof | PAICS, CES2, DNPEP | NPY5R 3699/4885NPY4R 4294/4885NPY1R 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.